Risk predictors for hypnosedative-related complex sleep behaviors: A retrospective, cross-sectional pilot study

Journal of Clinical Psychiatry

Volumn 71, Issue 10, 2010, Pages 1331-1335

  Hwang, Tzung Jeng ^a,b   Ni, Hsing Chang ^a   Chen, Hsi Chung ^a,c   Lin, Yi Ting ^a   Liao, Shih Cheng ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; HYPNOTIC SEDATIVE AGENT; ZOLPIDEM;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMAN; MALE; OBJECT MANIPULATION; PRIORITY JOURNAL; RISK ASSESSMENT; SLEEP DISORDER; SLEEP PATTERN; SLEEP WALKING; SOMATOFORM DISORDER; TAIWAN;

ANTIDEPRESSIVE AGENTS; AZABICYCLO COMPOUNDS; BENZODIAZEPINES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PILOT PROJECTS; PIPERAZINES; PYRIDINES; RETROSPECTIVE STUDIES; RISK FACTORS; SLEEP DISORDERS;

EID: 78149333494     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05083bro     Document Type: Article

References (40)

1. American Academy of Sleep Medicine. The International Classification of Sleep Disorders: Diagnostic and Coding Manual. 2nd ed. Westchester, IL: American Academy of Sleep Medicine; 2005.
2. Simmer ED. A fugue-like state associated with diazepam use. Mil Med. 1999;164(6):442-443. PubMed
3. Ansseau M, Poncelet PF, Schmitz D. High dose triazolam and anterograde amnesia. BMJ. 1992;304(6835):1178. doi:10.136/bmj.304.6835.178-b PubMed
4. Menkes DB. Triazolam-induced nocturnal bingeing with amnesia. Aust N Z J Psychiatry. 1992;26(2):320-321. doi:10.3109/048679209072046 PubMed
5. Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000;59(4):865-889. doi:10.2165/03495-2059040-014 PubMed
6. Soyka M, Bottlender R, Möller HJ. Epidemiological evidence for a low abuse potential of zolpidem. Pharmacopsychiatry. 2000;33(4):138-141. doi:10.105/s-20-124 PubMed
7. Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases. Int Clin Psychopharmacol. 1998;13(4):157-167. PubMed
8. Langtry HD, Benfield P. Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs. 1990;40(2):291-313. doi:10.2165/03495-1904020-08 PubMed
9. Sharma A, Dewan VK. A case report of zolpidem-induced somnambulism. Prim Care Companion J Clin Psychiatry. 2005;7(2):74. doi:10.408/PC.v07n0207a PubMed
10. Yang W, Dollear M, Muthukrishnan SR. One rare side effect of zolpidem-sleepwalking: a case report. Arch Phys Med Rehabil. 2005;86(6):1265-1266. doi:10.1016/j.apmr.204.1.02 PubMed
11. Morgenthaler TI, Silber MH. Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med. 2002;3(4):323-327. doi:10.1016/S1389- 9457(02)07-2 PubMed
12. Siddiqui F, Osuna E, Chokroverty S. Writing emails as part of sleepwalking after increase in zolpidem. Sleep Med. 2009;10(2):262-264. doi:10.1016/j.slep.208.09.08 PubMed
13. Tsai MJ, Tsai YH, Huang YB. Compulsive activity and anterograde amnesia after zolpidem use. Clin Toxicol (Phila). 2007;45(2):179-181. PubMed
14. Kintz P, Villain M, Dumestre-Toulet V, et al. Drug-facilitated sexual assault and analytical toxicology: the role of LC-MS/MS: a case involving zolpidem. J Clin Forensic Med. 2005;12(1):36-41. doi:10.1016/j.jcfm.204.08.05 PubMed
15. Pitner JK, Gardner M, Neville M, et al. Zolpidem-induced psychosis in an older woman. J Am Geriatr Soc. 1997;45(4):533-534. PubMed
16. Toner LC, Tsambiras BM, Catalano G, et al. Central nervous system side effects associated with zolpidem treatment. Clin Neuropharmacol. 2000;23(1):54-58. doi:10.1097/02826-2010-01 PubMed
17. Elko CJ, Burgess JL, Robertson WO. Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction. J Toxicol Clin Toxicol. 1998;36(3):195-203. doi:10.3109/1563659809028939 PubMed
18. Iruela L, Ibañez-Rojo V, Baca E. Zolpidem-induced macropsia in anorexic woman. Lancet. 1993;342(8868):443-444. doi:10.1016/0140-6736(93)92862-N PubMed
19. Iruela LM. Zolpidem and sleepwalking. J Clin Psychopharmacol. 1995;15(3):223. doi:10.1097/04714-195060-012 PubMed
20. Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992;41(3):237-248. doi:10.1016/0165- 1781(92)905-N PubMed
21. Tsai JH, Yang P, Chen CC, et al. Zolpidem-induced amnesia and somnambulism: rare occurrences? Eur Neuropsychopharmacol. 2009;19(1):74-76. doi:10.1016/j.euroneuro.208.08.07 PubMed
22. Lam SP, Fong SY, Ho CK, et al. Parasomnia among psychiatric outpatients: a clinical, epidemiologic, cross-sectional study. J Clin Psychiatry. 2008;69(9):1374-1382. doi:10.408/JCP.v69n0904 PubMed
23. Schenck CH, Hurwitz TD, Bundlie SR, et al. Sleep-related eating disorders: polysomnographic correlates of a heterogeneous syndrome distinct from daytime eating disorders. Sleep. 1991;14(5):419-431. PubMed
24. Huapaya LV. Seven cases of somnambulism induced by drugs. Am J Psychiatry. 1979;136(7):985-986. PubMed
25. Wills L, Garcia J. Parasomnias: epidemiology and management. CNS Drugs. 2002;16(12):803-810. doi:10.2165/023210-20216120-02 PubMed
26. Schenck CH, Mahowald MW. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med. 1996;100(3):333-337. doi:10.1016/S02-9343(97)89493-4 PubMed
27. 1 subtype. Nat Neurosci. 2000;3(6):587-592. doi:10.1038/75761 PubMed
28. A receptor subtypes. Nature. 1999;401(6755):796-800. doi:10.1038/4579 PubMed
29. Scharf MB, Fletcher K, Graham JP. Comparative amnestic effects of benzodiazepine hypnotic agents. J Clin Psychiatry. 1988;49(4):134-137. PubMed
30. Lloyd GK, Danielou G, Thuret F. The activity of zolpidem and other hypnotics within the gamma-aminobutyric acid (GABAA) receptor supramolecular complex, as determined by 35S-t-butylbicyclophosphorothionate (35S-TBPS) binding to rat cerebral cortex membranes. J Pharmacol Exp Ther. 1990;255(2):690-696. PubMed
31. Sanger DJ. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs. 2004;18(suppl 1):9-15, discussion 41, 43-45. doi:10.2165/023210-2041801-04 PubMed
32. A receptor subtypes. Eur J Pharmacol. 2002;451(2):103-110. doi:10.1016/S014-29(02)02191-X PubMed
33. Roehrs T, Merlotti L, Zorick F, et al. Sedative, memory, and performance effects of hypnotics. Psychopharmacology (Berl). 1994;116(2):130-134. doi:10.107/BF0245054 PubMed
34. Markowitz JS, Brewerton TD. Zolpidem-induced psychosis. Ann Clin Psychiatry. 1996;8(2):89-91. doi:10.3109/1040123960914806 PubMed
35. Verster JC, Volkerts ER, Schreuder AH, et al. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol. 2002;22(6):576-583. doi:10.1097/04714-202120-07 PubMed
36. Ohayon MM, Guilleminault C, Priest RG. Night terrors, sleepwalking, and confusional arousals in the general population: their frequency and relationship to other sleep and mental disorders. J Clin Psychiatry. 1999;60(4):268-276, quiz 277. PubMed
37. Hublin C, Kaprio J, Partinen M, et al. Prevalence and genetics of sleepwalking: a population-based twin study. Neurology. 1997;48(1):177-181. PubMed
38. Schenck CH, Connoy DA, Castellanos M, et al. Zolpidem-induced amnestic sleep-related eating disorder (SRED) in 19 patients. Sleep. 2005;28:A259.
39. Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet. 1995;29(3):142-153. PubMed
40. Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs. 2008;22(12):1021-1036. doi:10.2165/023210-2